---
title: Vertex Pharmaceuticals (VRTX)
layout: default
nav_order: 108
---

# Vertex Pharmaceuticals
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $67.4 B

Vertex Pharmaceuticals holds a solid, albeit niche, position in the cystic fibrosis (CF) market. Its dominance in this market gives it a degree of pricing power and creates high returns on capital. However, its dependence on a single disease presents substantial risks, and its venture into other therapeutic areas has yet to yield comparable success. Hence, a moat rating of 3 out of 5 seems appropriate.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=VRTX+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/VRTX/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat (3/5):**

* **Source of Moat:** Vertex enjoys near-monopoly status in the CF market, a classic example of a niche market moat as discussed in "The Little Book That Builds Wealth".  This affords significant pricing power, enabling high returns on invested capital.  The barriers to entry in the CF market are substantial due to the complex science and lengthy drug development processes.  This competitive advantage is also discussed extensively in McKinsey's "Valuation".
* **Moat Narrowing Factors:**  The company's heavy dependence on CF makes it vulnerable to competitive threats in this specific market and to the eventual loss of patent protection, a risk discussed in both "The Intelligent Investor" and "Common Stocks and Uncommon Profits".  While Vertex is working on expanding its CF franchise into adjacent patient groups, these efforts face inherent uncertainty. Further, its success in other therapeutic areas is uncertain, limiting its ability to diversify.

**Management (3/5):**

* **Strengths:**  The management team has delivered strong revenue and earnings growth historically, although this should be tempered by the limited scope of its product offerings.  Reshma Kewalramani, CEO since April 2020, has prior experience as Vertex's Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs, suggesting the experience needed to guide its current research & development efforts.
{: .note }
>
> During the Q3 2021 earnings call, Stuart Arbuckle, EVP and CFO stated, "Over the last five years, total revenue has grown at a compound annual growth rate of over 30% and non-GAAP product revenue at a compound annual growth rate of 36%."  The annual report of 2021 confirms this statement.
* **Weaknesses:**  Compensation levels for executives and directors are high, even after accounting for the company's strong financial performance, potentially creating incentives for value extraction rather than value creation, a risk highlighted in Warren Buffet's approach to management incentives as outlined in "The Essays of Warren Buffett". Insider ownership, while present, is not overwhelming. The company's singular focus on CF, despite substantial cash build-up, indicates a lack of promising investment opportunities beyond CF or a reluctance to diversify, a point made in “Valuation: Measuring and Managing the Value of Companies”.  The efficacy of their long-term capital allocation strategy beyond the CF space is yet to be seen.  These considerations justify a 3/5 rating.
{: .warning }
>
> As Michael Burry notes in his investment journal, "A company can fill in its own moat by investing heavily in areas in which it has no competitive advantage." (Journal entry, March 2001) While not explicitly stated by Vertex, a significant expansion into adjacent therapeutic areas such as pain and sickle cell disease requires a careful analysis to ensure that capital will not be wasted chasing opportunities where the company might not have the competencies to compete effectively.
**Catalyst (2/5):**

* **Pipeline:** The pipeline beyond CF is promising but faces substantial technological and commercial risks, as discussed extensively in "The Little Book That Builds Wealth." Approvals in pain or APOL1-mediated kidney disease would act as catalysts, but timelines for these potential future revenues are uncertain.
* **Exa-cel in Sickle Cell Disease and Beta Thalassemia:**  This gene-editing therapy has the potential to be a blockbuster but is still in late-stage clinical trials, hence the 2/5 catalyst rating. Regulatory approvals and market adoption are key uncertainties, highlighting the importance of scenario analysis as discussed in "Valuation."
{: .highlight }
>
>  As Reshma Kewalramani (CEO) noted in the Q1 2023 earnings call, "We're also very excited about exa-cel. We now anticipate our submissions in sickle cell disease and beta thalassemia to occur in the second half of this year." This suggests the potential for a catalyst if/when the regulatory authorities provide a positive signal.

**Business:**

Vertex currently generates almost all of its revenues from its CF franchise. In the last few years, Vertex has expanded its product offering for this disease and introduced several triple-combination therapies for different patient groups, which has been a key source of growth and profit.
{: .important }
>
> During the Q3 2022 earnings call Reshma Kewalramani (CEO) mentioned, "And the key metric that we're really proud of is revenue growth, and then profit growth." and "Our latest product, TRIKAFTA, with annualized revenue north of $8 billion, is off to a terrific start." These comments reflect the company's emphasis on revenue generation.

The CF market is small and specialized, allowing VRTX to dominate it but limiting the market opportunity. Vertex faces the challenge of sustaining its high growth rate. They are also attempting to diversify into other diseases, but it's uncertain whether their approach of developing therapies in house for difficult-to-treat diseases will provide another success comparable to CF. They have had several failures and setbacks as they explored these adjacent therapeutic areas.  The company continues to have significant amounts of cash available, which reflects its healthy operations but which could be more profitably redeployed with a better long-term capital allocation strategy. Competition in its current core market is low, and given Vertex's dominance, the company does not have much of a need to discount its product offerings to customers.

**Financials:**

Vertex has delivered very strong revenue and earnings growth over the past 5 years, largely driven by its CF franchise.  Margins are healthy, reflecting its pricing power. The company has no debt and a substantial cash balance, giving it significant financial flexibility.

{: .new }
>
>  "Our operating cash flow continues to be very strong", mentioned Reshma Kewalramani (CEO) in the Q1 2023 earnings call, "with year-over-year growth in excess of 50%, growing from $1.3 billion in Q1 '22 to $2 billion in the first quarter of '23." This statement suggests a very healthy financial position.

**Valuation (using a DCF Model):**

To arrive at a valuation, we used a Discounted Cash Flow (DCF) model, the valuation method favored by both Benjamin Graham and Warren Buffett.
We have built a DCF Model, based on the following assumptions (keeping in mind our pessimistic bias):

* **Revenue Growth:** We assume a growth rate of approximately 12% for the first five years, slowing from historical levels but reflecting continued growth from its CF portfolio.
* **Target Operating Margin:** We assume an operating margin of 38%.
* **Reinvestment Rate:** This is estimated based on projected revenue growth rates relative to earnings, and an assumed rate in perpetuity of 10%.
* **Cost of Capital (WACC):** We assume a WACC of 9%. This reflects a higher cost of equity compared to a conventional mature company due to the risk of its dependence on CF.
* **Terminal Value:** We use the stable growth formula to estimate terminal value using an expected RONIC of 12% in conjunction with a 3% perpetual growth rate.
* **Probability of Failure:** Given the risk related to diversification efforts, a 10% probability of failure over 10 years is incorporated into the valuation. We use a liquidation value of zero in the event of failure.


**Calculations:**

1. **Free Cash Flow (FCF):** This is calculated as (Operating Income) \* (1-Tax Rate) \* (1-Reinvestment Rate).
{: .highlight }
>
> Vertex does not provide details concerning capital expenditures and changes in non-cash working capital, hence we simply model its reinvestment rate. Also, the company does not include a tax reconciliation table in its financial statements so we assume a marginal tax rate of 25%.
2. **Present Value of FCF:**  Each year's FCF is discounted back to its present value using the 9% cost of capital.
3. **Terminal Value:**  The terminal value is computed at the end of the explicit forecast period (year 10).
4. **Present Value of Terminal Value:** This is discounted back to its present value using the 9% cost of capital.
5. **Enterprise Value (EV):** This is the sum of the present values of the FCFs and the terminal value.
6. **Equity Value:** This is the EV minus the market value of debt (which is zero for Vertex) plus cash.
7. **Value per Share:**  The equity value is divided by the number of shares outstanding.


{: .important }
>
> All the preceding steps lead us to a total enterprise value of approximately \$81 billion (unadjusted for the failure probability), which when divided by the number of shares outstanding yields a per-share value of around \$311. Assuming a probability of failure, the per share value drops to \$279 per share. This is approximately in line with the current market price.
{: .warning }
>
> It is worth noting that a 50% decrease in market price is roughly equally likely for low P/E ratio stocks as well as for the highest growth companies. The true differentiator is the degree of risk. Companies which appear likely to experience a substantial increase in their future profitability can have their P/E ratios jump spectacularly upward without producing any increase at all in intrinsic value.


**Conclusion:**

Vertex Pharmaceuticals is a complex company to value, given its dependence on the CF market. While it currently enjoys a dominant position, the challenges and uncertainties associated with achieving diversification and sustaining its growth rate justify a more cautious and nuanced valuation approach. While its current market price appears reasonable based on our valuation, this is predicated on its continued success in the CF market and requires careful monitoring of its pipeline in other therapeutic areas.  It's worth emphasizing the importance of continuously monitoring company updates, and financials to update the valuation as the company evolves.



